New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? (Q37684385)

22 August 2017

1 reference

title

New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis? (English)

1 reference

inflammatory bowel diseases

22 August 2017

main subject

0 references

author name string

S Danese

series ordinal

1

1 reference

22 August 2017

E Angelucci

series ordinal

2

1 reference

22 August 2017

publication date

1 June 2009

1 reference

Gastroenterologie Clinique et Biologique

22 August 2017

published in

1 reference

22 August 2017

volume

33 Suppl 3

1 reference

22 August 2017

page(s)

S217-27

1 reference

Inflammatory bowel disease: etiology and pathogenesis

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

The immunology of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Regulation of the mucosal epithelial barrier

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

IL-17 family cytokines and the expanding diversity of effector T cell lineages

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Unravelling the pathogenesis of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Interleukin-23 drives innate and T cell-mediated intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

T(H)-17 cells in the circle of immunity and autoimmunity

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Biologic therapy for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Biologic therapy of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Natalizumab therapy for moderate to severe Crohn disease in adolescents

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Natalizumab for induction of remission in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Association of glycogen storage disease 1b and Crohn disease: results of a North American survey

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Cyclic neutropenia in Crohn's ileocolitis: efficacy of granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Treatment of fistulas with granulocyte colony-stimulating factor in a patient with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Sargramostim for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Anti-interleukin-12 antibody for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

The immune system. First of two parts

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A preliminary study of growth hormone therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Interferon beta-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Interferon-beta-1a for the treatment of steroid-refractory ulcerative colitis: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

CNI-1493 mediated suppression of dendritic cell activation in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016/S0399-8320(09)73157-4

7 January 2021

10.1016/S0399-8320(09)73157-4

Identifiers

DOI

1 reference

22 August 2017

1 reference